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Obesity and the metabolic syndrome are systemic inﬂammatory diseases reaching epidemic proportions. Contemporary changes
in human nutrition occurred characterized by increased consumption of fat and of vegetable oils rich in n-6 polyunsaturated
fatty acids (PUFAs) together with decrease in n-3 PUFA-rich foods, resulting in an n-6/n-3 ratio of 10–20/1 in Western diet for
a ratio around 1/1 in the diet of our ancestors. The literature provides compelling evidence for the health beneﬁt of n-3 PUFA
consumption on inﬂammation and metabolic syndrome prevention and treatment. Such evidence led to the establishment of
comprehensive recommendations. However, we show here that, both in collective catering proposed to children and in hospital
diet, it is not straightforward to meet such recommendations. Willingness of governments to institute changes, with accountable
decisions on catering, nutritional education, and food processing, is required to face our neglected responsibility in promoting
balanced diet and consumptionof foods rich in essential nutrients in the general population.
1.Introduction
The metabolic syndrome (MetS) is deﬁned as a cluster
of symptoms such as visceral obesity, insulin resistance,
elevated blood pressure, and dyslipidemia, associated with
increased risk of type 2 diabetes, cardiovascular disease [1],
nonalcoholic fatty liver diseases (NAFLD) [2], and some
types of cancers [3]. This pathological condition is currently
reaching epidemic proportions (Figure 1) and may soon
represent the ﬁrst health issue worldwide in terms of
costs and mortality, even in developing countries. Although
multifactorial processes participating are yet to be unraveled,
there is a general agreement that the rising prevalence of
MetS is largely due to the increasing incidence of adiposity
[4]. Obesity, and in particular abdominal obesity or visceral
fat, as well as the MetS has been identiﬁed as low-grade and
systemic inﬂammatory conditions [5, 6], with an imbalance
between pro- and anti-inﬂammatory molecules and elevated
serum markers of inﬂammation [7]. Increased macrophage
inﬁltration in adipose tissue and possibly liver [8, 9], as well
as recruitment of lymphocytes [10]i sr e c o g n i z e dc a u s e so f
inﬂammation and insulin resistance in this context.
During the past 15 years, research eﬀorts have focused
on the primary factors responsible for the MetS and its
increasing prevalence worldwide. Contemporary to the rise
in MetS prevalence, important changes in human nutrition
and dietary habits were observed (Figures1 and 2) in parallel
with the adoption of a more sedentary life style, owing
to industrialization and drastic changes in strategies for
communication, crystallized under the emblematic so-called
“occidental way of life”. Consequently, this has resulted in a
disruption of the balance between energy intake and con-
sumption/expenditure, as well as relative excess/deﬁciency
in some metabolically relevant nutrients. Such modiﬁcations
are thought to be part of the MetS epidemic.
In particular, a steady increase in dietary reﬁned sugar
and fructose, that parallels the rise in obesity and diabetes, is
observed since the 70s due to the increased consumption of
soda, soft drinks, and manufactured candy and pastry [11]
and use of enriched (high) fructose corn syrup as sweetening
agent (Figure 1)[ 11, 12, 14]. Concomitantly, the rate of
fatty acid(FA)consumptionhasincreased. Indeed,in today’s
diet, FA represents 28%–42% of total energy consumed by
European populations [15], aﬀording 128g/d in developed2 Gastroenterology Research and Practice
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Figure 1: Evolution of Occidental dietary content in speciﬁc
macronutrients and prevalence of obesity and diabetes in United
States.Compiledfrom[11–13];FAO,AGROSTAT.PC, 1993;Centers
for Disease Control and Prevention, National Center for Health
Statistics, Division of Health Interview Statistics, data from the
NationalHealthInterview Survey;French NationalEpidemiological
Study on Overweight and Obesity: ObEpi-Roche 2009.
countries in 1990, while in 1961 it was estimated to
93g/d [16]. In ancestral nutrition, FA consumption was
approximated around 20%–30% of energy intake [17, 18].
Also, qualitative changes in the type of FA taken in have
occurred over the past 50 years, as depicted in Figure 2 for
European populations [13]. These changes are characterized
by increased consumption of saturated fat (especially from
meat), vegetable oils rich in linoleic acid (LA, n-6 PUFA)
on the one hand, and an overall decrease in n-3 PUFA
intakes relative to n-6 PUFA on the other hand [19]. This
was mainly attributable to insuﬃcient consumption of fatty
ﬁsh [20], reduced nuts, seeds, and whole-grain cereals in
alimentation [21] and a progressive preferential use of
saﬄower oil, poor in n-3 PUFA. Importantly, marine ﬁsh
and especially fatty ones are the most important source of
n-3 PUFA in the Occident. Aside from marine alga and
newly engineered oils and supplements [20, 22], marine
ﬁsh represent the only natural edible source of long-chain
(LC) n-3 PUFA eicosapentaenoic and docosahexaenoic acids
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Figure 2:EvolutionoffattyacidsconsumptioninEuropean Union.
Adapted from [13].
(EPA and DHA), the most biologically active n-3 PUFA
[23]. In Occidentalized countries, ﬁsh consumption is very
variable and globally low [24, 25]. Intensive farming could
also be an additional factor contributing to insuﬃcient
n-3 PUFA consumption as n-3 PUFA content in some
species of farmed ﬁsh, as rainbow trout [26], bream [27],
salmon coho, or catﬁsh [28], are reduced compared to their
wild counterparts. As a result, n-6 PUFA consumption has
become progressively much higher than that of n-3 PUFA
[29], so that Western diets have a n-6/n-3 ratio ranging from
10/1 to 20/1 for a ratio of 1/1 in the diet of our ancestors
[17, 30].
2.MetabolicConsequencesofAlteredFattyAcid
NutritionalIntakes
A body of epidemiological evidence highlights that high
consumption of saturated FAs and trans-FAs may have
adverse eﬀects on lipid and glucose homeostasis and evolu-
tion towards the MetS [31]. The mechanisms involved are
(i) the accumulation of toxic diacylglycerol and ceramides,
(ii) the activation of nuclear factor-κB, protein kinase C,
and mitogen-activated protein kinases which induce the
expression of inﬂammatory genes in adipose tissue and
immune cells, (iii) the decrease of peroxisome proliferator-
activated receptor (PPAR) α and adiponectin levels and
consequent decreased oxidation of FA and glucose, and (iv)
recruitment of immune cells in adipose tissue and muscle
[32].
The recent literature provides convincing evidence of the
detrimental role of low dietary n-3 PUFA for the MetS and
the cardiovascular risk. It has been shown that n-3 PUFA
in muscle membrane phospholipids are inversely related toGastroenterology Research and Practice 3
insulin resistance, whereas the amount of LA (n-6 PUFA)
incorporation into membrane phospholipids is positively
relatedtoinsulinresistance.Thelinksbetweenn-3PUFAand
MetS is conﬁrmed in many studies conductedindependently
around the world. For example, in The Multiple Risk Factor
Intervention Trial involving 6,250 middle-aged American
men determined to be at high risk of coronary heart dis-
eases, evaluation using four annual dietary recall interviews
showed that low n-3 PUFA consumption was associated
with increased mortality. On the contrary, no signiﬁcant
association with mortality was detected for LA (n-6), which
was the predominant dietary PUFA [33]. A study by Delavar
et al. involving 984 random sampled Iranian women (30–
50y) suggests that a diet that lacks n-3 PUFA and vitamins-
rich foodstuﬀs such as ﬁsh, vegetables, and nuts, increases
the likelihood of having MetS [34]. Similarly, in France, low
consumption of ﬁsh, and thus of n-3 PUFA, is associated
with a higher probability of MetS, as assessed on 912 men
(45–64y) [21].
Distinct beneﬁcial eﬀects of ﬁsh (LC n-3 PUFA) con-
sumption have been reported on insulin sensitivity, type 2
diabetes mellitus (T2DM), lipid proﬁle, and risk for death
from coronary heart diseases in healthy individuals [35–38]
or of α-linolenic acid (ALA) intake on reduced risk of
myocardial infarction [39]. Total n-3 PUFA supplies were
also associated with higher levels of anti-inﬂammatory
markers (soluble IL-6r, IL-10, TGFβ) in healthy adults [40].
Together, all those observations support that dietary n-3
PUFA may speciﬁcally inﬂuence the development of insulin
resistance and progression of the MetS, and associated
cardiovascular risk.
3.Metabolismof n-3 PUFA
FAs, whether saturated, mono- (MUFA) or polyunsaturated,
are oxidized in the mitochondria and represent the most
energetic substrates of the diet. They are incorporated
into phospholipids as the major components of cellular
membranes or packaged into triglycerides for storage and
export. The essential PUFA of the n-3 series (EPA and DHA,
found in ﬁsh oil and ALA, precursor of EPA and DHA,
found in nut, soy, and rapeseed oils) and of the n-6 series
(arachidonic acid -AA- and LA found in sunﬂower and nut
oils) are precursors for diﬀerent signaling molecules. Initial
steps in their metabolism are desaturations catalyzed by rate-
limiting Δ6a n dΔ5 desaturases (Figure 3). In humans, Δ5
and Δ6 desaturase activities, and thereby the conversion
rate of ALA to EPA/DHA, are low and can further be
modulated by genetic and epigenetic factors and dietary co-
factors, including magnesium, zinc, and vitamin B6 [44, 45].
Therefore, exogenous sources of EPA/DHA are important as
they generate the most potent n-3 PUFA-derived protective
mediators [23].
Site-speciﬁc oxygenation by cyclooxygenases (COX) and
lipoxygenases (LOX) produces diﬀerent signaling molecules
among which are eicosanoids, comprising prostaglandins
(PGs), thromboxanes, and leukotrienes (LTs) (see Figure 3)
[41–43]. While n-6 PUFA are substrates for synthesis of
proinﬂammatory eicosanoids(series2prostanoidsandseries
4 LT), n-3 PUFA metabolism rather yields less or anti-
inﬂammatory eicosanoidsamongst themseries3prostanoids
and series 5 LT [46]. Some of these LC metabolites (EPA,
DHA, PGI3, PGE1, and PGI2) may serve as endogenous
inhibitors of the angiotensin converting enzyme and HMG-
CoA reductase and as nitric oxide enhancers to produce
antihypertensive, anti-inﬂammatory, and antiatherosclerotic
eﬀects by acting on vascular cells, leukocytes, and platelets
[47] and function as signaling molecules via activation
of peroxisome proliferator-activated receptor (PPAR) tran-
scription factors regulating lipid metabolism [48]. There
is also increasing evidence that n-3 PUFA directly protect
against cellular aging and age-related diseases [49], possibly
through reduction of telomeres shortening in leukocytes
from patients with coronary heart disease [50]. Recently,
classes of autacoids as the E- and D-series resolvins, pro-
tectins, and maresin 1 derived from LC n-3 PUFA as well
as lipoxins derived from LC n-6 PUFA have been identiﬁed
as specialized mediators that stimulate host defense and
dampen inﬂammation, prevent platelet aggregation, lower
blood pressure, have antiarrhythmic action, reduce LDL
cholesterol, activate telomerase, and have cytoprotective
properties [36, 43, 46]. Whereas some of the eﬀects of
PUFA are undoubtedly mediated by eicosanoids, the PUFA-
mediated suppression of lipogenic and glycolytic genes
is independent of eicosanoids y n t h e s i sa n da p p e a r st o
involve a nuclear mechanism directly modiﬁed by PUFA
[51]. Thus, n-3 PUFA mediate anti-inﬂammatory, anti-
steatosis, and vascular protective eﬀects through several
mechanisms, including modiﬁcations in cell membrane
composition and function, gene expression modulation, or
distinct eicosanoids production.
Importantly, genetic polymorphisms in Δ5a n dΔ6
desaturase-encoding genes (FADS1 and FADS2) are asso-
ciated with variation in n-6 and n-3 PUFA content in
serum phospholipid fractions and tissues [52]. Also, poly-
morphisms alteringactivityofFADS1/2[52],LOX5[53],and
COX2 [54] genes products have been related to increased
deleterious eﬀects of n-6 PUFA, which were blunted by
increasing n-3 PUFA consumption. Acquired modiﬁcations
in enzymatic machinery metabolizing PUFA have been
described in association with obesity, insulin resistance,
and cancer [48, 54]. High-energy diet, SFA, and transfats
during perinatal period have been shown to repress the
expression of Δ5a n dΔ6 desaturases in both maternal and
fetal tissues and inﬂuence PUFA metabolism in adulthood,
representing an additional mechanism for decreased tissue
and membrane LC n-3 PUFA [55]. Interestingly, relevant
to the characterized consequences of diet for epigenetics
[56], Devlin et al. reported hypermethylation of FADS 2
gene promoter associated to decreased Δ6 desaturase activity
and DHA levels in the liver in a nutritional model of
hyperhomocysteinemia [45].
This clearly underlies that, beside nutrition, genetic
factors, concurrent pathological conditions, and epigenetic
modiﬁcations also play an important role in the regula-
tion of LC-PUFA metabolism and may thus inﬂuence the
developmentof inﬂammatory and metabolic diseases. It also4 Gastroenterology Research and Practice
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Figure 3: Metabolism of polyunsaturated fatty acids and their signaling molecules. Adapted from [41–43]. The 3D plasma layer image was
modiﬁed from the one provided by M´ elanieVilleneuve,Lacelluleanimale,CCDMD, 2008(http://www.ccdmd.qc.ca/ri/cellule/index.php?nh
=18).
suggests interindividual variations for requirements in n-3
PUFA.
4.n-3 PUFA and Beneﬁtsinthe Metabolic
Syndrome
Next to epidemiological evidence, literature provides a
profusion of data reporting that increased n-3 PUFA con-
sumption in intervention studies may alleviate metabolic
and cardiovascular risk. Thus, consistent with the inverse
correlation found between ﬁsh and ﬁsh oil consumption
and biomarkers of inﬂammation (TNFα,I L 6 ,C R P )i nm a n y
populations (healthy adults -[40, 57]; patients with insulin
resistance [58]; coronary heart disease [59]; or the MetS
[44, 60]), dietary enrichment in n-3 ALA and in EPA/DHA
reduced low grade inﬂammation in at-risk populations
[61–64].
Despite a relatively low accumulation in adipocytes [41],
LC n-3 PUFA elicit beneﬁcial eﬀects on adipose tissue in
obesity, as indicated by (i) reduced body fat mass and
stimulated lipid oxidation [65], (ii) improvement of body
weight and satiety regulation [66], (iii) amelioration of
cytokines proﬁle, including leptin and adiponectin [66], and
(iv) reduction of inﬂammation [44, 60]. Additionally, n-3
PUFA havebeen shown to reduceadipose tissue macrophage
inﬁltration associated with obesity in animal models [67],
but this requires conﬁrmation in humans.
Human trials conﬁrmed that LC n-3 PUFA from either
ﬁsh or ﬁsh oil supplements as well as ALA enrichment
signiﬁcantly reduce blood triglyceride levels in patients with
MetS in a dose-dependent manner [35, 68], an eﬀect that
appears to be mediated through inhibition of hormone-
sensitive lipase and VLDL secretion, and increase in apo B
liver degradation [35].
A body of evidence demonstrates that n-3 PUFA
are involved in the control of glucose homeostasis and
insulin sensitivity [69]. In murine models of obesity and
insulin resistance, incorporation of LC n-3 PUFA into
cell membrane phospholipids increases membrane ﬂuidityGastroenterology Research and Practice 5
and expression, aﬃnity, and number of insulin receptors
[58]a sw e l la sG L U T - 4p r o t e i nl e v e li na d i p o c y t e s[ 70],
thereby improving insulin sensitivity. In overweight patients,
n-3 PUFA reduce transition from glucose intolerance to
T2DM [29], and ﬁsh and ﬁsh oil consumption during
energy reduction elicit an additional positive eﬀects on
insulin resistance [71]. However, a majority of n-3 PUFA
administration trials did not prove eﬃcient in reducing
insulin resistance in T2DM [29].
Diet interventions with increased n-3 PUFA clearly
demonstrated therapeutically, reliability in lowering mor-
tality in subjects with cardiovascular diseases or the MetS
[31, 72], an eﬀect primarily related to increased DHA
intakes [73]. This justiﬁes the recommendation for daily
consumption of 1g/d of LC n-3 PUFA as part of secondary
prevention strategy post ischemic heart event [74].
NAFLD, now recognized as the hepatic complication
of the MetS, might trigger development of T2DM. Low
dietary n-3 PUFAcontentinduceshepatic desaturase activity
[75]. In addition, enzymes involved in eicosanoid synthesis
are located at the periphery of lipid droplets [76]. It is
therefore plausible that in the context of diet- or obesity-
induced fatty liver associated with excessive n-6/n-3 ratio,
hepatic eicosanoid production is tilted towards proinﬂam-
matory components and participates to proinﬂammatory
and insulin resistant status aggravating the MetS. Animal
diet-induced obesity experiments clearly show that EPA and
DHA supplementation reduces severity of NAFLD, if not
preventing it [23], suggesting that increasing n-3 PUFA
intake and ﬁsh consumption might prevent the occurrence
of NAFLD in humans [2]. Properly conducted clinical trials
are awaited to conﬁrm this.
Asimportant,emergingevidenceindicatesthatincidence
and tumour growth of some cancers associated with the
MetS can be attenuated by n-3 PUFA [3]. Independently
of the total amount of n-3 PUFA, the n-6/n-3 ratio seems
to be determinant as a ratio of 2.5/1 reduced rectal cell
proliferation in patients with colorectal cancer, whereas a
ratio of4/1 with the same amount of n-3 PUFA had no eﬀect
[77].
5.Recommendationsfor
n-3 PUFA Consumption
From the above, it is obvious that there is a need for
recommendations for n-3 PUFA nutritional supplies both
for the prevention of MetS and associated disorders in
the general population and for secondary prevention or
treatment. Establishing such guidelines represents a com-
plex issue for three main reasons. First, there is a large
interindividual variability in n-3 PUFAmetabolism based on
genetic determinants, gender and age, further magniﬁed by
concurrent associated diseases or epigenetic modiﬁcations.
Therefore, ideal requirement for physiological eﬀect needs
to be tailored for a speciﬁc individual [52–54, 78]. Secondly,
dietary composition, for example, high dietary SFA or high
n-6 PUFA, interferes with the biological eﬀects of n-3
PUFA [31, 77]. The consequences of excessive n-6 PUFA
remain controversial: n-6 PUFA have intrinsic cardiovascu-
lar protective eﬀects [79], justifying the latest FAO/WHO
recommendations on maintaining high n-6 PUFA intakes
if n-3 PUFA ones are fulﬁlled [80]. However, n-6 PUFA
compete with n-3 PUFA for processing to eicosanoids,
thereby limiting production of antiinﬂammatory n-3 PUFA
derived mediators [46]. Moreover, there are convincing
evidence that a low n-6/n-3 PUFA ratio is determinant
for the prevention of pathologies associated to the MetS,
as colorectal cancer [77]a n dN A F L D[ 81–83]. Thus, we
propose that n-3 PUFA recommendations must be part of
a more global dietary counseling and should be associated
with maximum reduction in SFA and limitation of n-6
PUFA intakes to their recommended levels(from 5% to 10%
energy intake in Europe and USA [79], resp.). The n-6/n-
3 PUFA ratio is a good indicator of this balance. Thirdly,
there are concerns about availability of certain foodstuﬀs
(such as wild ﬁsh) and food contaminants, as seafood, rich
in LC n-3 PUFA, is also a dietary source of heavy metals
(methylmercury), polychlorinated biphenyls, dioxins, and
other organic pollutants [84].
Deduced from ancestral nutrition, in an ideal balanced
diet, fat should represent no more than 20%–30% of total
energy intake amongst which 5-6g/d of n-3 PUFA with a
great proportion of EPA+DHA and the n-6-to-n-3 ratio
should average 1 [17, 30]. To keep in with a developmental
approach and with the epigenetic consequences of the diet
[56], a ratio of n-6/n-3 around 1 in breast milk should
serve as a bench mark to determine the appropriate dietary
requirementsduringpregnancy,lactation, andinfant feeding
[85].
Previously, health organizations and government agen-
cies in most western countries recommended daily con-
sumption of 0.6 to 1g n-3 PUFA from which 100–200mg
of LC n-3 PUFA (EPA+DHA). However, in intervention
studies reporting a beneﬁcial health eﬀect, the consumption
of ﬁsh oils or their derivatives resulted in LC n-3 PUFA
daily intakes well above those “recommended” 200mg/day
and ranged from 0.5 to 9g/d. Indeed, in a meta-analysis, a
37% reduction in the relative risk of coronary heart disease
in the general population was seen with a daily intake of
EPA/DHA of 566mg. Therefore, this justiﬁes readjustments
of nutritional guidelines to an upper level. Governments
(France, Belgium, UK, The Netherlands, New Zeeland, and
Australia) and health organizations (FAO/WHO, American
Dietetic Association, American Heart Association) now
recommend dietary intakes for total n-3 PUFA of 1.4 to
2.5g/d, with EPA and DHA ranging from 140 to 600mg/d
depending on the authority issuing guidelines, FOA/WHO
making a relatively low recommendation of 250mg/d, the
average being around 500mg/d [80, 86, 87]. This represents
minimum of 2 servings of ﬁsh per week (30–40g/d),
including one of oily ﬁsh (salmon, tuna, mackerel, and
sardine). In the light of the literature and interindividual
variability in PUFA metabolism and requirement, probably
the minimal EPA+DHA supplies for healthy adults should
reach 0.5–1g/d (2–4 servings per week of ﬁsh, half of oily
ﬁsh); that is, minimal consumption proved to reduce MetS
[86], with a total intake of n-3 PUFA of 5-6g/d as found6 Gastroenterology Research and Practice
in ancestral nutrition to which our metabolism is best ﬁt
[18, 51]. Such levels are met in the traditional Japanese diet
as it contains 80–100g ﬁsh and shellﬁsh/d/capita [88].
6.Are These RecommendationsFollowed?
To address this question, we calculated FA composition
in meals proposed by nutritionist coordinated collective
caterings to which health is of concern: ﬁrst, in lunches
supplied by the township of Lille (France) to healthy pupils
(4–6 and 6–9y) and adults and second, in meals proposed to
patients hospitalized in St. Luc University Hospital (Brussels,
Belgium).
Total content in FA and speciﬁc contents in SFA, MUFA,
PUFA, n-6, n-3, and LC n-3 PUFA were calculated in menus
over 6 representative weeks for the township collective cater-
ingofLilleandin4weekswintermenusand4weekssummer
menus, proposed in rotation along the year by the university
hospital. Three types of menus were analyzed: normal, for
diabetic patients, and low fat. We used (i) the oﬃcial table
of composition in saturated, mono- and polyunsaturated
FA of foodstuﬀs provided by the French Agency for Food
Safety [89], (ii) the table of composition in n-6 and n-
3 PUFA of ﬁsh, meat, oils, and dairy provided either by
the project “Nutritional Composition of Aquatic Products”
[27] or by the French Institute for Nutrition [90], and (iii)
the EPA and DHA contents of speciﬁc foodstuﬀsp r o v i d e d
by the USDA National Nutrient Database for Standard
Reference [28]. The ANC guidelines [91] were taken as
reference for daily recommended intakes (DRI) and calcu-
lated lunch daily recommended intakes (LDRI) as 35%–40%
ofDRI,witharange representingminimumsuppliesforgirls
and maximum ones for boys.
Results are presented in Table 1. In collective lunches
proposed by the township of Lille whether to children or
adults, the mean contents in FA and SFA were relatively
high, estimated at 117%–141% and 116%–149% of LDRI,
respectively, and MUFA supplies were relatively insuﬃcient
(59%–91%). However, supplies in both total and n-6 PUFA
exceeded LDRI by 200%–300%. This is related to systematic
replacement of processed fats with saﬄower oil (rich in n-6)
as the main dressing and cooking oil. Strikingly, n-3 PUFA
contents were low, representing only 68%–91% of LDRI,
although there were 8 servings of ﬁsh over the 6 weeks
menus, 4 servings were white ﬁsh (1.2% fat), 2 canned tuna
(4.1% fat), and 2 salmon (11.8% fat), but one of which as
small portion served as baked pasta dish. As a result, n-6/n-3
ratio was dramatically elevated (18,6–24,1/1).
In the meals proposed at St. Luc University Hospital,
total FA were relatively low (66%–74% of DRI and 48% of
DRI in low fat menus), SFA were in the recommended range
or below, but MUFA were dramatically low (38% of DRI
and 27% for low fat). Recommended amounts of total and
n-6 PUFA were supplied in classical and low-fat diets, but
they were outleveled in the diabetic regimen, owing to the
addition of 2 saﬄower-based dressings per day for lunch and
evening salads. Regarding n-3 PUFA, the content in total n-3
PUFA was between 1.8 and 1.9g/d and that of LC n-3 PUFA
(EPA+DHA) of 460mg/day. Those are close to or within the
recommendations [91]. Thus, n-6/n-3 ratio varied from 5/1
to 8/1 (the ideal being 1/1, the recommendation 4/1, and
currently in the global population 20/1). It is of note that
the quasiadequate amounts of n-3 PUFA and LC n-3 PUFA
are supplied owing to the presence of 2 portion/d (breakfast,
diner) of an n-3 PUFA-enriched margarine containing 16%
n-3 PUFA and 0.5% EPA+DHA. This represents 1.2g/d n-
3 PUFA and 0.2g/d EPA+DHA, without which n-3 PUFA
supplies would be insuﬃcient with an n-6/n-3 ratio higher
than 15.
Thus, consistent with other reports [17, 29, 30, 77],
despite increasing awareness and nutritionist-assisted food
catering, reaching adequate or recommended n-3 PUFA
supplies in collective nutrition still needs eﬀective and
applicable solutions. For reﬂection, in in-hospital catering,
replacement of white ﬁsh by fatty ﬁsh in one serving has
been discussed in order to try to overtake minimum DRI
for n-3 PUFA and reduce n-6/n-3 ratio (particularly in
menus for diabetic subjects). In school catering, increasing
the use of rapeseeds oil (59% MUFA, 20% n-6, and 9%
n-3) in replacement of saﬄower oil (20% MUFA, 64% n-
6 and 0.2% n-3) for 50% of the dressings was considered.
Forecast calculations show that this would greatly participate
in reducing excessive n-6, PUFA intake (−2g/d)andincrease
both MUFA (+1,6g/d) and n-3 PUFA (+0,4 g/d) intakes,
resulting in a half reduction of n-6/n-3 ratio (9,5 versus 20).
This appears as a simple measure, easily implemented, while
very eﬀective. As exempliﬁed in results from hospital menus,
the incorporation of enriched manufactured products such
as n-3 PUFA-enriched margarine is an alternative to com-
pensate for insuﬃcient supply of natural products.
7.HowCouldWeModifyOur Diet to
Improve n-3 Intakes?
Fish and oils rich in ALA (ﬂaxseed, canola, soybean, walnut)
represent the main sources of n-3 PUFA. As conversion
rate from ALA to EPA/DHA is low in humans, a minimum
part of the recommended nutritional supplies in n-3 PUFA
should beprovidedasmarine LC PUFA(500mg/d).The ﬁrst
eﬀective measure for increasing n-3 PUFA intakes should
consist in actively promoting ﬁsh consumption, to reach 35–
40g ﬁsh/d. Ideally, wild ﬁsh should be given the preference
as some species have a higher n-3 PUFA content and/or a
lower n-6/n-3 ratio than farmed ones, which usually contain
more n-6 PUFA [26–28, 92] partially owing to alimentation.
Given the declining stocks of marine ﬁsh and high pollution
in some ﬁshing areas, this is most likelynot a sustainable and
globally applicable solution.
An additional measure is to use ALA rich oils, as
envisaged in school catering. For example, replacement of
dressing oils rich in n-6 PUFA (mainly saﬄower oil) by oils
rich in n-3 PUFA (ﬂaxseeds, walnuts, wheat germ, rapeseeds,
and soybean) provides a substantial additional n-3 PUFA
supply (15g walnuts oil = 1.5g ALA = 2 dressings) while
decreasing n-6 intake. However, such modiﬁcations require
nutritional education and education to diﬀerent tastesGastroenterology Research and Practice 7
Table 1: Daily fatty acids supplies in municipal and hospital catering.
FA
Total g (% LDRI) SFA g (% LDRI) MUFA g (% LDRI) PUFA g (% LDRI)
Lille municipal catering
Children 4–6 y 28,3 (141%) 8,5 (139%) 8,4 (91%) 10,3 (381%)
LDRI min-max 16,5–23,8 a5,5–6,8 6,6–11,9 1,3–4,1
Children 6–10 y 30,0 (117%) 9,1 (116%) 9,0 (76%) 10,7 (310%)
LDRI min-max 20,9–30,2 a7,0–8,6 8,4–15,1 1,7–5,2
Adults 32,6 (117%) 10,0 (149%) 9,9 (59%) 11,3 (265%)
LDRI min-max 23,1–32,4 a5,6–7,8 14,0–19,6 3,5–5,0
St. Luc Hospital, Brussels
Classic 48,28 (66%) 18,38 (104%) 16,79 (38%) 13,10 (116%)
b11,90 (105%)
Diabetic 54,15 (74%) 20,16 (114%) 17,52 (39%) 16,47 (146%)
b15,27 (135%)
Low-fat 35,36 (48%) 12,64 (71%) 12,07 (27%) 10,64 (95%)
b9,44 (84%)
DRI women-men 66–81 a16,0–19,5 40,0–49,0 10,0–12,5
PUFA
n-6 PUFA g (% DRI) n-3 PUFA g (% DRI) EPA+DHA g (% DRI) n-6/n-3 ratio (% DRI)
Lille municipal catering
Children 4–6 y 9,9 (441%) 0,4 (91%) 0,16 24,1 (482%)
LDRI min-max 1,1–3,4 0,2–0,7 5,00
Children 6–10 y 10,2 (359%) 0,5 (82%) 0,22 20,8 (415%)
LDRI min-max 1,4–4,3 0,3–0,9 5,00
Adults 10,8 (316%) 0,6 (68%) 0,27 (130%) 18,6 (466%)
LDRI min-max 2,8–4,0 0,7–1,0 0,20 4,00
St. Luc Hospital, Brussels
Classic 11,24 (125%) 1,92 (85%) 0,46 (93%) 5,86 (147%)
b0,72 (32%) b0,26 (53%) b15,61 (390%)
Diabetic 14,66 (163%) 1,85 (82%) 0,46 (92%) 7,91 (198%)
b0,65 (29%) b0,26 (52%) b22,55 (563%)
Low-fat 8,90 (99%) 1,79 (80%) 0,46 (93%) 4,96 (124%)
b0,59 (26%) b0,26 (53%) b15,08 (377%)
DRI women-men 8,0–10,0 2,0–2,5 0,50 4,00
LDRI: lunchdaily recommended intakes[91]; numbers in bracketscorrespond to the % of average DRI/LDRI; aFor SFA, values represent the range of 35% of
the maximum intakesfor women and 40% of the maximum intakes for men; bValues without enriched margarine.
(oils rich in n-3 PUFA have pronounced tastes), probably
easier to integrate onto the developing palette of taste during
infancy. As edible wild plants provide higher amounts of
ALAand antioxidants than intensively cultivated plants[39],
encouraging agricultural methods that are more respectful
of developmental cycles and natural nutritional contents of
plants would help increase n-3 PUFA consumption.
Consideration has also to be brought to the cooking
methods as n-3 PUFA are highly sensitive to oxidation by
oxygen, light, and heat, leading to production of deleterious
free radicals. Indeed, cooking ﬁsh might reduce by up to
50% its content in n-3 PUFA [93]. Thus consumption of
freshly harvested raw (or cooked at low heat) ﬁsh and raw
n-3 PUFA-rich oils should be promoted.
Food enrichment is emerging as perhaps the best long-
term solution to the chronically low intake of n-3 PUFA
that plagues western cultures [87]. First, n-3 PUFA-rich
oils should more systematically replace n-6 PUFA-rich oils
in industrial preparations. Second, eﬀorts are being made
to produce a variety of food products, most notably eggs,
yogurt,milk, andspreads, enriched with n-3 PUFA-richfood
[94]. Alternatively, n-3 PUFA synthesis might be induced
by genetic manipulation. This has been done in plants by
transgene-driven expression of Δ6 desaturase. In derived
oil, LC n-3 PUFA concentration amounts those found in
native marine organisms [95]. At the experimental level,
this application has been extended to mice. Indeed, the
team of Kang realized a stable transfection of FADS3 from
C. Elegans, an enzyme missing in mammals which catalyses
conversion of n-6 to n-3 PUFA [96]. This resulted in
spontaneous enrichment of their lipids with n-3 PUFA. Such
experiment might pave the way to genetic manipulation of
cattle and poultry to produce n-3 PUFA-rich raw material.
Innumerable ethical, ecological, economical, and cultural
issues need to be addressed prior to generalization of such
experimental trials.8 Gastroenterology Research and Practice
8.ConcludingRemarks
The literature provides compelling evidence for the health
beneﬁt of n-3 PUFA consumption not only on the MetS,
cardiovascular risks, and associated comorbidities but also
on other conditions such as neuroinﬂammatory and neu-
rodegenerative diseases. This evidence must be taken into
consideration, and eﬀorts have to be made to promote
increased n-3 PUFA consumption together with lowering
intakes of high glycemic food, fructose, and fat, in particular
SFA and n-6 PUFA when clearly excessive, and increasing
ingestion of fruits, vegetables, whole grains, and nuts.
Despite this awareness, what is still needed is an educational
program for professionals and for the public [17]a sw e l la s
manifestation of the willingness of governments to institute
changes, notably through achieving accountable decisions
on catering (as undertaken here) as well as modiﬁcations of
food processing and industrial food ingredients legislations,
all towards promoted use and preservation of n-3 PUFA
rich food. Increasing experimental evidence supporting the
pivotal roles of nutrition in the regulation of homeostasis
highlight ourneglected responsibility in promotingbalanced
diet and consumption of food rich in essential nutrients in
the general population.
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